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included in the national Dutch influenza vaccination pro-
gram, that encompasses the elderly of 65 years and older.
The objective of this study is to estimate the cost and ben-
efits of vaccinating healthy working adults aged 25 to 64
years against influenza.
METHODS: Our cost-benefit analysis includes the direct
and indirect costs associated with vaccination as well as
the direct and indirect costs avoided by vaccination. The
underlying model links influenza incidence to health-care
resource use, work absenteeism and productivity loss.
Health-care resource use was specified for general practi-
tioner visits, hospitalizations and drugs. Clinical and eco-
nomical parameter estimates were derived from pub-
lished literature and Dutch registry data.
RESULTS: Vaccinating healthy working adults aged 25
to 44 years costs € 0,39 per person per year. Vaccinating
persons aged 45 to 64 years saves € 1,51 per person per
year. On the population level, vaccinating persons aged
25–44 years costs about € 1,4 million per year, vaccinat-
ing persons aged 45-64 years saves about € 2,3 million
per year. On average, vaccinating healthy working adults
saves € 0,9 million. The indirect costs prevented prima-
rily determine the cost-benefit outcome of vaccination for
healthy working adults.
CONCLUSIONS: Influenza vaccination of healthy work-
ing adults is cost saving. These findings support routine
vaccination for this group, from the employer’s perspective.
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OBJECTIVES: Toenail onychomycosis is the most com-
mon nail fungal infection. If left untreated, it can evolve
into a more severe stage that can involve the matrix. The
clinical management of patients remains constraining and
long. In addition, relapses occur frequently after antifun-
gal treatment. This has significant socio-economic im-
pact. Combining topical and oral antifungals can increase
cure rates and decrease treatment duration. The Ony-
choTree project aims at providing an evaluation tool to
estimate economic consequences of the management of
severe toenail onychomycosis in Europe.
METHODS: The methodology for OnychoTree develop-
ment follows a rigorous stepwise design to obtain an inter-
national model, valid for use across 17 countries: 1) an ex-
tensive literature review of international data on toenail
onychomycosis; 2) the design of a core clinical manage-
ment-decision tree; 3) the validation and completion of the
core model (treatment patterns and medical resource use)
by an expert panel of 12 dermatologists from six countries;
4) expansion and validation of the model to 11 additional
countries through advisory panel interviews assessing na-
tional specificities (disease management and associated
costs); 5) a meta-analysis of efficacy rates from relevant
clinical trials of antifungals; 6) cost-effectiveness analyses.
RESULTS: The initial common model was designed from
the available international literature. The expert panel
clinicians confirmed their interest for: 1) a clinical man-
agement model, and 2) cost-effectiveness evaluation in-
cluding new combination therapies. They requested ad-
aptations to reflect country-specific medical practice.
After adaptation, they validated the core European phar-
macoeconomic model. Advisory panel interviews con-
firmed these results, focusing on the need for country-
specific analyses based on a common decision tree.
CONCLUSIONS: Cost-effectiveness analyses including
the 17 country-specific data will be performed with the
final model. These European results will make both med-
ical professionals and the public aware of the possible im-
provement in health-care resource use for the manage-
ment of severe toenail onychomycosis.
PIN11
A COST BENEFIT ANALYSIS OF TWO 
ALTERNATIVE MASS IMMUNIZATION 
PROGRAMS WITH A CONJUGATE VACCINE 
AGAINST MENINGOCCOCAL DISEASE TYPE C
Simons WR1, Rancourt C2, Grégoire JP2, Dostie A2
1Global Health Economics and Outcomes Research Inc, Short 
Hills, NJ, USA; 2Merck Frosst Canada Ltd, Kirkland, QC, Canada
OBJECTIVE: We conducted a cost-benefit analysis of
two approaches to manage a regional outbreak of sero-
group C meningococcal disease (MCD): 1. a planned
mass immunization program (MIP) of 2,000,000 Quebec
residents aged 2 months to 20 years, that would be im-
plemented in September 2001; 2. an emergency MIP im-
plemented at the peak of subsequent outbreaks.
METHODS: As a reference case, we used the scenario
that occurred in Quebec in 1991—several targeted re-
gional vaccination programs were implemented in an at-
tempt to ward off a more widespread outbreak of MCD.
Unfortunately, at the end of 1992, public-health authori-
ties had to implement a province-wide emergency MIP.
We assessed the benefit of the programs using epidemio-
logical data from the previous cycle of MCD in Quebec.
Benefits included the number of new MCD cases pre-
vented by the administration of Menjugate™ and their
associated hospital and societal costs due to premature
mortality and related morbidity. Costs included acquisi-
tion and administration cost of the conjugate vaccine,
clerical, physician and health-services costs, and those re-
lated to lost productivity. We conducted the analysis in a
societal perspective assuming Quebec would face a simi-
lar epidemiological situation in 2001 as the one that
started in 1991. All costs were transformed into 2001
Canadian dollars at an annual inflation rate of 3%.
RESULTS: Over a 12-month period, a planned MIP
would prevent 127 new cases (18 deaths, 24 major com-
plications) while saving $15.0 million in direct costs to
